TargetMol
GSK 3 Inhibitor IX (6-BIO) is a selective reversible, ATP-competitive inhibitor of GSK-3α/β and CDK1-cyclinB complex. It inhibits (GSK-3α/β)/CDK1/CDK5 activity with IC50 values of 5 nM/320 nM/83 nM, respectively.
More Information
Supplier Page
TargetMol
GSK 3 Inhibitor IX (6-BIO) is a selective reversible, ATP-competitive inhibitor of GSK-3α/β and CDK1-cyclinB complex. It inhibits (GSK-3α/β)/CDK1/CDK5 activity with IC50 values of 5 nM/320 nM/83 nM, respectively.
More Information
Supplier Page
TargetMol
TargetMol
Nateglinide is an oral hypoglycemic agent and amino acid derivative that stimulates insulin secretion from the pancreas and is used in the therapy of type 2 diabetes. Nateglinide has been linked to rare instances of clinically apparent acute liver injury.
More Information
Supplier Page
TargetMol
DL-o-Tyrosine is a metabolite of Phenylalanine and is a precursor in the formation of catecholamines. It is used as biomarkers of protein oxidative damage in β-thalassemia.
More Information
Supplier Page
TargetMol
DL-o-Tyrosine is a metabolite of Phenylalanine and is a precursor in the formation of catecholamines. It is used as biomarkers of protein oxidative damage in β-thalassemia.
More Information
Supplier Page
SN-38
100 mg
| 99.97%
TargetMol
TargetMol
2′-Deoxyuridine. An antimetabolite that is converted to deoxyuridine triphosphate during DNA synthesis. Laboratory suppression of deoxyuridine is used to diagnose megaloblastic anemias due to vitamin B12 and folate deficiencies.
More Information
Supplier Page
TargetMol
Enhances CRISPR-Cas9-mediated homology-directed repair (HDR) efficiency in vitro up to 19-fold. Inhibits nonhomologous end-joining (NHEJ).
More Information
Supplier Page
TargetMol
Enhances CRISPR-Cas9-mediated homology-directed repair (HDR) efficiency in vitro up to 19-fold. Inhibits nonhomologous end-joining (NHEJ).
More Information
Supplier Page